Brainsway Ltd. has reported impressive financial results for the third quarter of 2026, demonstrating a significant increase in both revenue and profitability. The company, known for its advanced non-invasive neurostimulation treatments, is positioned well in the surgical and medical instruments industry.

In its recent filing, Brainsway disclosed that revenue grew by 34% to $18.1 million, up from $13.5 million in the same quarter last year. Operating income surged by 107%, reaching $2.6 million, while adjusted EBITDA increased approximately 92% to $3.9 million. This strong financial performance reflects the growing adoption of Brainsway's Deep TMS technology and the company's effective business model.

Background

Brainsway Ltd. is a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, incorporated in Israel. The company operates under the SIC classification of Surgical & Medical Instruments & Apparatus (SIC 3841) and is publicly traded on the Nasdaq and OTC markets under the tickers BWAY and BRSYF. The recent filing, dated November 10, 2026, is part of a series of 6-K submissions that highlight the company's ongoing operational updates.

What the Filing Says

The filing includes a report on Brainsway's third-quarter financial results, stating, "Our third-quarter results demonstrate our ability to translate strong revenue growth into higher profitability and cash generation." CEO Hadar Levy emphasized the company's focus on expanding reimbursement coverage and increasing utilization of their technology.

Impact

This financial update is significant not only for Brainsway but also for the broader industry, as it showcases the potential for growth in the neurostimulation market. The company’s performance could influence competitors in the surgical and medical instruments sector, particularly those involved in mental health treatments.

What's Next

Brainsway's management will host a conference call on November 10, 2026, to discuss these results further. The filing does not specify any additional immediate actions beyond this call.